JOINN (06127) has released its interim results for the 2026 fiscal year, recording revenue of approximately RMB 704 million, a 5.3% increase year-on-year. Profit attributable to equity shareholders for the period reached roughly RMB 748 million, marking a significant surge of about 11.27 times compared to the same period last year, with earnings per share standing at RMB 1.
During the reporting period, the company's total on-hand order value amounted to approximately RMB 3.7 billion, reflecting a 60.9% year-on-year growth. Newly signed orders reached around RMB 2.02 billion, up 98.0% year-on-year. The announcement attributes the rise in net profit primarily to changes in the fair value of biological assets.
Comments